The Institute for Immunology and Informatics (iCubed) was established in 2008 under the leadership of Annie De Groot, M.D. and Denice Spero, Ph.D., as part of the University of Rhode Island’s emerging Biotechnology Program. The Institute maintains offices and laboratory space in the historic Shepard Building as part of URI’s Feintstein Providence Campus.
The Institute applies cutting-edge bioinformatic tools to accelerate the development of treatments and cures for a number of diseases such as hepatitis C, lyme disease and Dengue fever. The Institute also aims to quickly make these tools available to the global research community for the development of vaccines for other infectious diseases.
iCubed’s research focuses on new and safer vaccines and new methods of predicting and treating adverse immune responses. iCubed supports a wide variety of training efforts that will provide opportunities to teach the next generation the tools for effective vaccine design. For more information on the training sessions, please visit our Events page.
Mission: To improve human and animal health by applying the power of immunomics (immunoinformatics, genomics and immunology) to the design of better vaccines, diagnostics, and therapeutics.
Vision: The vision of the founding members of the Institute for Immunology and Informatics is to develop Rhode Island into a globally recognized center for Biotechnology Vaccine Research. We anticipate that Rhode Island will achieve international standing for scientific contributions in both vaccine research and research on adverse reactions to protein drugs.
Focus: To conduct research at the interface between new immunology discoveries, new immunoinformatics technologies and prevention and treatment of human and animal disease.
New Biological Entities
Biotechnology is a rapidly expanding field leading to the development of new medicines, agricultural products, and immuno-therapeutics such as monoclonal antibodies and vaccines. New Biological Entities (NBEs) comprising therapeutic proteins, vaccines and antibodies, provided biotech companies with revenues of greater than $70 billion in 2007 (Ernst and Young). NBE approvals nearly doubled in the United States in the last decade (Center for Study of Drug Development/Tufts University 2011). While some universities have been slow to respond to the demand for qualified graduates, the University of Rhode Island (URI) has embraced this opportunity and has been rapidly expanding the number of biotech-related educational offerings over the past few years.
With the addition of the Institute of Immunology and Informatics (iCubed) in 2008, URI has become a recognized leader in the field of vaccine discovery. iCubed investigators and collaborators (through the $13 million TRIAD U19 grant from the National Institutes of Health) are fully invested in transferring their knowledge and experience in these complex issues surrounding vaccine discovery to the next generation of scientists. Training is one of the core missions of the iCubed, as is development of safer, more effective, genome-derived vaccines.
iCubed Focus: Faster, Safer and Fewer Vaccines for the 21st Century
Excitement about vaccines is palpable. While they are certainly the greatest safeguard of human health, saving literally millions of lives per year, new ideas about using vaccines to treat cancer and autoimmune disease are generating significant interest in academia and industry. Research on new vaccines is leading to the introduction of novel materials such as naked DNA, crab-shell derived chitosan vaccine delivery vehicles, and insect-cell produced antigens to name just a few. The fact that there are no effective vaccines for emerging infectious diseases lends even greater urgency to vaccine research. Faster, safer vaccine development is a critical area of US research focus, according to the Health and Human Services Secretary Kathleen Sebelius, who said that the US must build a “21st century medical countermeasure enterprise that is modern, flexible, and equipped to respond quickly and effectively to any threats that arise”. The need for this nation-wide effort to improve vaccine design and production was illustrated by industry-wide delays in the development of a vaccine for the pandemic strain of H1N1 swine flu. The iCubed is currently funded through the $13 million TRIAD CCHI (U19 Center grant) and is actively contributing to national efforts to speed the design and development of vaccines, including selection of safer and more efficient delivery methods that are critically important to advance vaccines in the next century.
A Unique Approach
The iCubed excels in immunoinformatics-driven vaccine development, colloquially known as “gene-to-vaccine”. The approach involves computer-driven analysis of genome sequences, selection of immunogenic segments, and composition of vaccines in silico. The next step in the process is to validate the vaccine candidates in vitro and in vivo, using methods developed in the iCubed laboratories. A wide array of vaccine delivery technologies are under evaluation, including monoclonal antibodies (Moise), liposomes (Bothun, De Groot), and DNA vaccines (De Groot with the Department of Defense). Using immunoinformatics tools, research also is being conducted on eliminating parts of vaccines that may contribute to deleterious immune responses (Rothman). Collaborations extend internationally to Thailand (Dengue virus, Rothman), and Mali (HIV, TB, HPV, De Groot). Research collaborations have been developed with Steve Williams (filaria, Smith College), another investigator who is involved in the iCubed program. Each of these cross-cutting areas of research, comprising experience that covers the biotech field ‘from gene to vaccine’ is currently being integrated into the activities of the iCubed.
Industry Leaders lending their skills to iCubed Translational program
Drs. Annie De Groot and Denice Spero co-direct iCubed. Collectively, Drs. De Groot and Spero, have over 40 years of combined experience leading biotechnology and pharmaceutical drug discovery programs. They joined forces in the iCubed, where they have made it their mission to train the next generation of researchers to design safer, more efficacious, and more accessible vaccines. They actively coordinate their training opportunities with Greg Paquette, Director of the Biotechnology and Manufacturing program and Edward Bozzi, Associate Professor Clinical, under the College of the Environment and Life Sciences (CELS). Currently, undergraduate and Master’s-level URI students are exposed to iCubed research and have access to biotechnology courses and hands-on laboratory experiences through the Biotechnology program at CELS. At the iCubed, students are able to engage in Ph.D.-level research and training in vaccine and biologics development lead by iCubed researchers.
The iCubed has access to tools for “genes-to-vaccines” development that were originally developed by Dr. De Groot at EpiVax, Inc. (a iCubed industry partner). These tools are being successfully applied to the design of vaccines for Tularemia, Burkholderia (biodefense agents), HIV, TB, HCV, Tick-borne-disease, and H. pylori by iCubed researchers. Additional collaborations at the iCubed are designing new vaccines for the equine encephalitis viruses WEE/EEE/VEE (biodefense agents, in collaboration with EpiVax and the Department of Defense) and young researchers were trained to apply the tools to Neglected Tropical Diseases (NTD’s) over the past year. The tools allow rapid scanning of bacterial and viral genomes for highly immunogenic components and the rapid concatenation of these components in a delivery vehicle (such as a plasmid or pseudoprotein). The prototype vaccines are validated in vitro (in HLA binding and T cell assays) and in vivo (in HLA transgenic mice). Areas of active research also include elimination of epitopes that are cross-conserved with the human microbiome. Collectively, iCubed’s approaches are gaining industrial acceptance when selecting the best lead candidates to carry forward from preclinical to clinical development, and are reducing the risk of failure in the clinical setting.
iCubed Economic Impact
Rhode Island is actively developing its knowledge economy with a concerted effort by local businesses, universities, hospitals and government officials, and Drs. Spero and De Groot have been drivers in this effort. For example, Drs. Spero and DeGroot hold a highly successful course for entrepreneurship. This cross-institutional collaboration teaches scientists and business-trained individuals the principles of biotechnology start-up with a focus on companies that support vaccine research. This course has been repeatedly profiled as a success story in Providence by the business community and both academic and industry leaders participate in teaching the course. The focus of this course is to create jobs in Rhode Island.Clearly, staring businesses and hiring employees has a direct economic impact on the state.
Projects that have garnered Federal Interest
The Department of Defense (DOD) and the NIH are highly interested in vaccine-related research, and are actively funding projects in vaccines for infectious diseases, biodefense, neglected tropical diseases, and vaccine delivery vehicles. These federal institutions are engaged in funding projects that bring new therapeutics to the patient, so called translational research. The iCubed currently is funded through NIH grants that focus both on education as well as research in translational vaccine design for emerging infectious diseases and biodefense agents.